KURA vs PUBM Comparison

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

PubMatic is one of the leading supply-side platform providers in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, better manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). PubMatic generates revenue mainly via taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Given the growth in overall digital advertising, more publishers and advertisers are adopting programmatic (or automated) buying and selling, driving the firm's success in attracting more inventory.